A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors
Clinical trial NCT04606472 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04606472
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-11-10
- Primary completion
- 2025-12-01
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.